Skip to main content

Advertisement

SpringerLink
Log in

Are we missing the mTOR target in breast cancer?

  • Invited Commentary
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

The Original Article was published on 16 October 2010

The Original Article was published on 14 October 2010

The Original Article was published on 13 October 2010

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S et al (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3(8):772–775

    Article  PubMed  CAS  Google Scholar 

  2. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X et al (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65(7):2554–2559

    Article  PubMed  CAS  Google Scholar 

  3. Shoman N, Klassen S, McFadden A, Bickis MG, Torlakovic E, Chibbar R (2005) Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol 18(2):250–259

    Article  PubMed  CAS  Google Scholar 

  4. Inoki K, Corradetti MN, Guan KL (2005) Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37(1):19–24

    Article  PubMed  CAS  Google Scholar 

  5. Hara K, Yonezawa K, Kozlowski MT, Sugimoto T, Andrabi K, Weng QP et al (1997) Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem 272(42):26457–26463

    Article  PubMed  CAS  Google Scholar 

  6. Chung J, Grammer TC, Lemon KP, Kazlauskas A, Blenis J (1994) PDGF- and insulin-dependent pp70S6K activation mediated by phosphatidylinositol-3-OH kinase. Nature 370(6484):71–75

    Article  PubMed  CAS  Google Scholar 

  7. Eng CP, Sehgal SN, Vezina C (1984) Activity of rapamycin (AY-22, 989) against transplanted tumors. J Antibiot (Tokyo) 37(10):1231–1237

    Article  CAS  Google Scholar 

  8. Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P et al (2001) mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8(3):249–258

    Article  PubMed  Google Scholar 

  9. O’Reilly T, Vaxelaire J, Muller M et al (2002) In vivo activity of RAD-001, an orally active rapamycin derivative, in experimental tumor models. Proc Am Assoc Cancer Res 43(71):Abstract 359

  10. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J et al (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22(12):2336–2347

    Article  PubMed  CAS  Google Scholar 

  11. O’Donnell A, Faivre S, Burris HA 3rd, Rea D, Papadimitrakopoulou V, Shand N et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26(10):1588–1595

    Article  PubMed  Google Scholar 

  12. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C et al (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23(23):5314–5322

    Article  PubMed  CAS  Google Scholar 

  13. Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O’Reilly T, Evans DB et al (2005) Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 11(14):5319–5328

    Article  PubMed  CAS  Google Scholar 

  14. deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM et al (2004) Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 10(23):8059–8067

    Article  PubMed  CAS  Google Scholar 

  15. Baselga J, Fumoleau P, Gil M, Colomer R, Roche H, Cortes-Funes H et al (2004) Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results. Proc Am Soc Clin Oncol 23(13):A544

    Google Scholar 

  16. Baselga J, Roche H, Fumoleau P, Campone M, Colomer R, Cortes-Funes H et al (2005) Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combinations with temsirolimus; a randomized 3-arm, phase 2 study. Breast Cancer Res Treat 94(Suppl 1):A1068

    Google Scholar 

  17. Chow LWC, Jassem J, Baselga J, Hayes DF, Woff AC, Hachemi S et al. (2006) Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 97(Suppl 1):Abstract 6091

  18. Macaskill JE, Bartlett JMS, Sabine VS et al (2010) The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study. Breast Cancer Res Treat. doi:10.1007/s10549-010-0967-z

  19. Pérez-Tenorio G, Karlsson E, Waltersson MA et al (2010) Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer. Breast Cancer Res Treat. doi:10.1007/s10549-010-1058-x

  20. Margariti N, Fox SB, Bottini A, Generali D (2010) Overcoming breast cancer drug resistance with mTOR inhibitors. Could it be a myth or a real possibility in the short-term future? Breast Cancer Res Treat. doi:10.1007/s10549-010-0986-9

  21. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A’Hern R et al (2007) Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99(2):167–170

    Article  PubMed  CAS  Google Scholar 

  22. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J et al (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27(16):2630–2637

    Article  PubMed  CAS  Google Scholar 

  23. Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M et al (2007) Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 13(20):6064–6069

    Article  PubMed  CAS  Google Scholar 

  24. Sabatini DM (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6(9):729–734

    Article  PubMed  CAS  Google Scholar 

  25. O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66(3):1500–1508

    Article  PubMed  Google Scholar 

  26. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H et al (2005) Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65(16):7052–7058

    Article  PubMed  CAS  Google Scholar 

  27. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K et al (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26(10):1603–1610

    Article  PubMed  CAS  Google Scholar 

  28. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A et al (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6(11):1122–1128

    Article  PubMed  CAS  Google Scholar 

  29. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712):1098–1101

    Article  PubMed  CAS  Google Scholar 

  30. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M et al (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68(19):8022–8030

    Article  PubMed  CAS  Google Scholar 

  31. Yao J, Phan A, Chang D, Jacobs C, Mares JE, Rashid A et al (2006) Phase II study of RAD001 (everolimus) and depot octreotide in patients with advanced low grade neuro-endocrine carcinoma (LGNT). Proc Am Soc Clin Oncol 24:Abstract 4042

  32. Di Cosimo S, Bendall JC, Cervantes-Ruiperez A, Roda D, Prudkin L, Stein MN et al (2010) A phase I study of the oral mTOR inhibitor ridaforolimus in combination with the ICF-1R antibody in patients with advanced solid tumours. Proc Am Soc Clin Oncol 28(15S):Abstract 3008

  33. Markman B, Atzori F, Perez-Garcia J, Tabernero J, Baselga J (2010) Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol 21(4):683–691

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Royal Marsden Hospital, Fulham Road, Chelsea, London, SW3 6JJ, UK

    Stephen R. D. Johnston

Authors
  1. Stephen R. D. Johnston
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen R. D. Johnston.

Additional information

This is an invited commentary to articles doi: 10.1007/s10549-010-0967-z, 10.1007/s10549-010-0986-9, 10.1007/s10549-010-1058-x.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johnston, S.R.D. Are we missing the mTOR target in breast cancer?. Breast Cancer Res Treat 128, 607–611 (2011). https://doi.org/10.1007/s10549-010-1207-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-010-1207-2

Keywords

Search

Navigation